logo-loader
viewVolitionRx

VolitionRx to join Russell 3000, Microcap Indexes

The company will be added as part of the indexes' annual reconstitution at the close of trading on Friday

stock charts
Volition's inclusion in the indexes will stand for at least the next year

VolitionRx Limited (NYSEAMERICAN:VNRX), an epigenetics company, is joining the ranks of the Russell 3000 and Russell Microcap Indexes when they reconstitute at the close of trading on Friday, the company announced.

Roughly $9 trillion in assets are benchmarked against Russell Indexes in the US, the company said.

"Inclusion in the Russell Indexes is an important achievement for Volition,” CEO Cameron Reynolds said in a statement. “It is a testament to the significant progress we've made as a company over the past few years, and we believe that membership will provide further visibility within the financial community and greater liquidity in our shares."

READ: VolitionRx CEO to present coronavirus white blood cell research at Maxim Group virtual conference

Reynolds also released a business update video for investors.

"We look forward to introducing a wider investor audience to our platform and growth story, and to continuing to execute on our strategy in the second half of the year with several important milestones, including advancing our trials and an expected product launch, that further us on the path toward long-term value creation."

The company’s inclusion in the indexes will stand for at least the next year. 

Volition is developing easy to use blood tests to help diagnose a variety of cancers and other diseases.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 3.67 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $169.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRX encouraged by early data on its Nu.QTM blood test as potential...

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds tells Proactive's Andrew Scott they've been investigating how its Nu.QTM platform might be clinically useful as either a diagnostic or prognostic tool for COVID-19 and that they've been encouraged by some of the early data. He says...

on 05/08/2020

2 min read